Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Surgery and anesthesia may compromise fragile brain function in the elderly, potentially precipitating cognitive decline or Alzheimer's disease (AD) following perioperative neurocognitive disorder (PND). Vasoactive intestinal peptide (VIP) exhibits anti-inflammatory properties via the gut-brain axis. Nevertheless, whether VIP regulation enhances cognitive function in the fragile brains of aged rat and the underlying mechanisms remain to be elucidated.
Methods: A model of fragile brain function was established in elderly rats through bilateral common carotid artery ligation. Cognitive impairment induced by anesthesia and surgery was evaluated using behavioral assays, quantification of cognition-related protein levels, analysis of inflammatory markers, assessment of microglial polarization, and examination of intestinal mucosal and blood-brain barrier integrity. Adeno-associated virus (AAV) was employed to upregulate VIP expression in the colon, and subsequent alterations in the aforementioned parameters were recorded.
Results: Cognitive performance was evaluated through behavioral assays, while cognition-related protein levels were determined using Western blot analysis. Anesthesia and surgical interventions exacerbated cognitive deficits in rats with fragile brain function. VIP upregulation significantly ameliorated post-anesthesia and surgery cognitive deficits, normalized cognition-related protein expression, attenuated the inflammatory response, and promoted the repair of both intestinal mucosal and blood-brain barriers.
Conclusion: These findings indicate that VIP upregulation mitigates anesthesia- and surgery-induced cognitive impairment and its progression in aged rats with fragile brain function a, primarily by modulating the inflammatory response and preserving the gut and blood-brain barrier integrity. This study offers valuable insights potential preventive strategies against cognitive decline.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.expneurol.2025.115328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FMR1 mutant marmosets show fragile X syndrome phenotypes.
Cell Rep
August 2025
Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address:
Fragile X syndrome (FXS) is the foremost monogenic cause of autism spectrum disorder and intellectual disability, caused by FMR1 gene silencing. Here, we report that common marmosets carrying FMR1 mutation, a non-human primate model for FXS, share common features in behavioral and molecular phenotypes with patients with FXS. Founder mutants with markedly reduced fragile X messenger ribonucleoprotein expression display hyperactivity, spontaneous seizures, and transcriptome changes in synapse-related genes that overlap with those reported in patients with FXS.
View Article and Find Full Text PDFFmr1 knockout disrupts multiple intrinsic properties via reduced HCN channel activity in mediodorsal thalamocortical neurons.
Exp Physiol
September 2025
Department of Neurology, Dell Medical School at The University of Texas at Austin, Austin, Texas, USA.
The neurodevelopmental disorder fragile X syndrome (FXS) results from hypermethylation of the FMR1 gene, which prevents production of the FMRP protein. FMRP modulates the expression and function of a variety of proteins, including voltage-gated ion channels, such as hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels, which are integral to rhythmic activity in thalamic structures. Thalamocortical pathology, particularly involving the mediodorsal thalamus (MD), has been implicated in neurodevelopmental disorders such as FXS.
View Article and Find Full Text PDFPreliminary perspectives on gene therapy in fragile X syndrome: a caregiver view.
J Neurodev Disord
September 2025
University of Edinburgh, Patrick Wild Centre and Simons Initiative for the Developing Brain, George Square, Edinburgh, UK.
Background: There have been increasing numbers of clinical trials of medications for fragile X syndrome (FXS) in recent years, many targeted at proposed underlying cellular or circuit based mechanisms. As yet none of these have led to widespread changes in clinical practice. Genetic therapies represent a different therapeutic approach, which aim to address the genetic mechanisms by which FXS arises.
View Article and Find Full Text PDFROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.
Transl Psychiatry
August 2025
Department of Psychology, University of Oklahoma, Norman, OK, USA.
Fragile X Syndrome (FXS) is a rare neurodevelopmental disorder caused by a trinucleotide repeat expansion on the 5' untranslated region of the FMR1 gene. FXS is characterized by intellectual disability, anxiety, sensory hypersensitivity, and difficulties with executive function. A recent phase 2 placebo-controlled clinical trial assessing BPN14770, a first-in-class phosphodiesterase 4D allosteric inhibitor, in 30 adult males (age 18-41 years) with FXS demonstrated cognitive improvements on the NIH Toolbox Cognitive Battery in domains related to language and caregiver reports of improvement in both daily functioning and language.
View Article and Find Full Text PDFSevere Elimination Disorders and Normal Intelligence in a Case of Related Syndrome: A Case Report.
Genes (Basel)
July 2025
División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Mexico.
Pathogenic variants in the gene have been associated with neurological impairment, including intellectual disability, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, brain malformations, cognitive hearing loss, short stature, and dysmorphic features. However, few cases with detailed clinical characterization have been reported. We describe a 12-year-old boy carrying a loss-of-function variant, presenting with severe elimination disorders despite normal intelligence.
View Article and Find Full Text PDF